Search Result

Results for "

94-09-7

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (2) Calcium Channel (1) Environmental Pollutants (1) Isotope-Labeled Compounds (1) Reference Standards (1) Sodium Channel (5)
By Research Areas:	Infection (1) Neurological Disease (5)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-Y0258

Benzocaine 1 Publications Verification	Environmental Pollutants Sodium Channel Bacterial	Infection Neurological Disease
Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca ²⁺, with an IC₅₀ of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals .

HY-Y0258R

Benzocaine (Standard) 1 Publications Verification	Reference Standards Sodium Channel Bacterial	Neurological Disease
Benzocaine (Standard) is the analytical standard of Benzocaine (HY-Y0258). This product is intended for research and analytical applications. Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca ²⁺, with an IC₅₀ of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals .

HY-Y0258A

Benzocaine (hydrochloride) 1 Publications Verification	Sodium Channel Calcium Channel	Neurological Disease
Benzocaine hydrochloride is an orally active local anesthetic. Benzocaine hydrochloride non-competitively inhibits the binding of Ca-ATPase to Ca ²⁺, with an IC₅₀ of 47.1 mM. Benzocaine hydrochloride exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine hydrochloride induces methemoglobinemia in various experimental animals .

HY-Y0258S1

Benzocaine-(ethyl-d5)	Sodium Channel	Neurological Disease
Benzocaine-(ethyl-d₅) is the deuterium labeled Benzocaine (HY-Y0258). Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca ²⁺, with an IC₅₀ of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals .

HY-Y0258S

Benzocaine-d4	Isotope-Labeled Compounds Sodium Channel	Neurological Disease
Benzocaine-d₄ is the deuterium labeled Benzocaine (HY-Y0258). Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca ²⁺, with an IC₅₀ of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals .

Cat. No.	Product Name	Chemical Structure

HY-Y0258S1

Benzocaine-(ethyl-d5)
Benzocaine-(ethyl-d₅) is the deuterium labeled Benzocaine (HY-Y0258). Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca ²⁺, with an IC₅₀ of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals .

HY-Y0258S

Benzocaine-d4
Benzocaine-d₄ is the deuterium labeled Benzocaine (HY-Y0258). Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca ²⁺, with an IC₅₀ of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.